1. Home
  2. CIK vs INO Comparison

CIK vs INO Comparison

Compare CIK & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

SELL

Current Price

$2.34

Market Cap

127.8M

Sector

Finance

ML Signal

SELL

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

SELL

Current Price

$1.45

Market Cap

118.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CIK
INO
Founded
N/A
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.8M
118.9M
IPO Year
1995
1999

Fundamental Metrics

Financial Performance
Metric
CIK
INO
Price
$2.34
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $5.33
AVG Volume (30 Days)
419.3K
★ 14.3M
Earning Date
01-01-0001
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.18
EPS
★ N/A
N/A
Revenue
N/A
★ $42,220,086.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 19.37
52 Week Low
$2.26
$0.56
52 Week High
$2.88
$2.72

Technical Indicators

Market Signals
Indicator
CIK
INO
Relative Strength Index (RSI) 62.48 62.51
Support Level $2.26 $1.08
Resistance Level $2.40 $1.85
Average True Range (ATR) 0.03 0.20
MACD 0.01 0.09
Stochastic Oscillator 91.67 64.88

Price Performance

Historical Comparison
CIK
INO

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Share on Social Networks: